References
- Zhang W, Cheng SY, Hou LF, et al. Genomics in personalized cancer medicine and its impact on early drug development in China: report from the 6th Annual Meeting of the US Chinese Anti-Cancer Association (USCACA) at the 50th ASCO Annual Meeting. Chin J Cancer 2014;33(8):371-5
- Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature 2012;490(7418):61-70
- Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360(8):765-73
- Zhang W. TCGA divides gastric cancer into four molecular subtypes: implications for individualized therapeutics. Chin J Cancer 2014;33(10):469-70
- TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell 2013;155(2):462-77
- Yang D, Khan S, Sun Y, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011;306(14):1557-65
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11-30
- Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497(7447):67-73
- Salvesen HB, Carter SL, Mannelqvist M, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A 2009;106(12):4834-9
- Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 2011;11(8):597-608
- Liu YX, Patel L, Mills GB, et al. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst 2014;106(8; dju245
- Myers A, Barry WT, Hirsch MS, et al. beta-Catenin mutation in recurrent FIGO IA grade 1 endometrioid endometrial cancers. Gynecol Oncol 2014;134(2):426-7
- Matias-Guiu X, Prat J. Molecular pathology of endometrial carcinoma. Histopathology 2013;62(1):111-23
- Mhawech-Fauceglia P, Wang D, Samrao D, et al. Trefoil factor family 3 (TFF3) expression and its interaction with estrogen receptor (ER) in endometrial adenocarcinoma. Gynecol Oncol 2013;130(1):174-80
- Liu C, Li Y, Semenov M, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002;108(6):837-47
- NCI. Available from: www.cancer.gov/drugdictionary?cdrid=696436
- Liu J, Pan S, Hsieh MH, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci USA 2013;110(50):20224-9
- Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 2014;20(13):3379-83
- Ramirez PT, Frumovitz M, Bodurka DC, et al. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 2004;95(1):133-8
- Feliciano P. Inhibitors of mutant IDH1 and IDH2. Nat Genet 2013;45(5):477